Zentiva inks €220M deal to commercialize AstraZeneca GI cast-off in Europe
Former Sanofi subsidiary Zentiva has bought in to an ex-AstraZeneca asset for gastric acid-related diseases, forging a 220-million-euro alliance with Cinclus Pharma to commercialize and manufacture linaprazan glurate in Europe.
Former Sanofi subsidiary Zentiva has bought in to an ex-AstraZeneca asset for gastric acid-related diseases, forging a 220-million-euro alliance with Cinclus Pharma to commercialize and manufacture linaprazan glurate in Europe.
.png?cb=486e63f3912bcde2d9a2136714c1a880#)
